-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever) Drug...
-
Product Insights
NewLassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Lassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes, and bleeding. The antiviral drug ribavirin seems to be an effective...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Favipiravir in Lassa Fever (Lassa Hemorrhagic Fever)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Favipiravir in Lassa Fever (Lassa Hemorrhagic Fever) Drug Details: Favipiravir (Avigan) is an antiviral agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Carcinoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Carcinoid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Carcinoid Tumor Drug Details: Cabozantinib s-malate (XL184,...
-
Product Insights
NewAutoimmune Technologies LLC Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Autoimmune Technologies LLC Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Autoimmune Technologies LLC (Autoimmune Technologies) operates as a biomedical company that offers research and laboratory testing services. The company offers research services in areas of MERS and SARS, influenza, hepatitis c, sjogren's syndrome, dengue fever, ebola fever and lassa fever, and graves' disease, among others. Its laboratory testing services comprise tests for fibromyalgia, ebola fever, lassa fever, gulf war...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details:Vaccine is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lassa Fever Vaccine in Lassa Fever (Lassa Hemorrhagic Fever)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lassa Fever Vaccine in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details:Vaccine candidate is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARN-75039 in Lassa Fever (Lassa Hemorrhagic Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARN-75039 in Lassa Fever (Lassa Hemorrhagic Fever) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARN-75039 in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details: ARN-75039 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Melanoma Drug Details: MP-0310 is under development for the treatment of solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Primary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Primary CNS Lymphoma Drug Details: Zanubrutinib (Brukinsa) acts as an antineoplastic agent. It...